Date: 2015-08-27
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France- Austria) The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) (Japan)
Therapeutic area: undisclosed
Type agreement: licensing
Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012.
Disease: undisclosed
Details: * On August 27, 2015, Valneva SE, a leading pure-play vaccine biotech company, announced that it has signed a new research license agreement with Kaketsuken to develop a novel human vaccine candidate using its EB66® cell line. The new agreement follows two marketing approvals which were granted to Kaketsuken by the Japanese health authorities for an EB66® -based pandemic H5N1 influenza vaccine in March 2014 and for an EB66® -based prototype vaccine against any strain of pandemic influenza in March 2015. The Company further anticipates that Kaketsuken will be awarded a first stockpiling contract by the Japanese government in 2015 leading to first royalties for an EB66® based human vaccine upon vaccine delivery from 2016 onwards. Prior to the licenses signed with Fatro and Kaketsuken, Valneva entered into five new agreements in the first half of 2015, including licenses to Chinese firm Jianshun Biosciences Ltd and to Merial, the animal health division of Sanofi. Valneva also granted Boehringer Ingelheim a 10-month extension to its current research license in return for an extension fee.
Financial terms:
Latest news:
